Anti-Human AXL Recombinant Antibody (Humanized 11B7) (CAT#: TAB-1098CL)

Figure 1 Orthotopic xenograft model to investigate the effects of rat anti- AXL antibodies on human prostate carcinoma growth in nude mice.

PC-3-LN prostate carcinoma cells were orthotopically implanted into the prostate of NMRI-nu/nu mice. Animals were randomized into 4 groups and received 25 mg/kg of the isotypic control antibody 1 D5 or the antagonistic rat anti-AXL antibody 11B7, as well as 40 mg/kg Sutent or 12.5 mg/kg Taxotere. During the treatment period, the growth of orthotopically growing PC-3-LN tumors as well as peripheral metastases was monitored once weekly via in vivo bioluminescence imaging on day 15, day 23, day 29, and day 34. Compared to the isotypic control antibody 1 D5, the antagonistic rat anti-AXL antibody 11B7 reduced the overall growth of PC-3-LN prostate tumors in nude mice.

Figure 2 Orthotopic xenograft model to investigate the effects of rat anti- AXL antibodies on human prostate carcinoma metastasis in nude mice.

PC-3-LN prostate carcinoma cells were orthotopically implanted into the prostate of NMRI-nu/nu mice. Animals were randomized into 4 groups and received 25 mg/kg of the isotypic control antibody 1 D5 or the antagonistic rat anti-AXL antibody 11B7, as well as 40 mg/kg Sutent or 12.5 mg/kg Taxotere. Post necropsy, selected organs (liver, spleen, lung, femur, and a part of the lumbar spine) were collected and analyzed for the presence of metastases via bioluminescence imaging. Compared to the isotypic control antibody 1D5, the antagonistic rat anti-AXL antibody 11B7 reduced the occurrence of spleen metastases. Noteworthy, the anti-metastatic effect of 11 B7 in this experiment was stronger than that of Sutent.

Figure 3 This figure describes binding activity of the rat anti-human AXL humanized antibodies h#11B7-T1 to h#11B7-T6 determined by ELISA using human AXL-Fc coated plate.

Figure 4 This figure describes binding activity of the rat anti-human AXL humanized antibodies h#11B7-T7 to h#11B7-T13 determined by ELISA using human AXL-Fc coated plate.

Figure 5 This figure describes binding activity of the rat anti-human AXL humanized antibodies h#11B7-T14 to h#11B7-T20 determined by ELISA using human AXL-Fc coated plate.

Figure 6 This figure describes binding activity of the rat anti-human AXL humanized antibodies h#11B7-T21 to h#11B7-T27 determined by ELISA using human AXL-Fc coated plate.

Figure 7 This figure describes binding activity of the rat anti-human AXL humanized antibodies h#11 B7-T28 to h#11B7-T31 determined by ELISA using human AXL-Fc coated plate (ELISA).

Figure 8 These figures describes determination of Tm of the rat anti-human AXL humanized antibodies h#11B7-T1 determined by differential scanning calorimetry (DSC).